|
KMID : 0939920200520041288
|
|
대한암학회지
2020 Volume.52 No. 4 p.1288 ~ p.1290
|
|
|
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
|
|
Park Seh-Hoon
Ku Bo-Mi
Jung Hyun-Ae
Sun Jong-Mu
Ahn Jin-Seok
Lee Se-Hoon
Park Keun-Chil
Ahn Myung-Ju
|
|
|
Abstract
|
|
|
|
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, Lazertinib, Third-generation EGFR tyrosine kinase inhibitor, ErbB receptors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|